A Phase I study of setmelanotide FluidCrystal for the treatment of life-threatening obesity due to rare and serious genetic disorders.
Phase of Trial: Phase I
Latest Information Update: 26 Oct 2017
At a glance
- Drugs Setmelanotide (Primary)
- Indications Obesity
- Focus Adverse reactions; Pharmacokinetics
- 26 Oct 2017 According to a Camurus media release, final results from this trial are expected in Q4 2017.
- 27 Jun 2017 Initial results published in a joint media release by Rhythm and Camarus.
- 07 Jan 2016 New trial record